| Business Summary | | The
Immune
Response
Corporation
is
a
biopharmaceutical
company
developing
immune-based
therapies
to
induce
specific
immune
responses
for
the
treatment
of
HIV,
autoimmune
diseases
and
cancer.
In
addition,
the
Company
is
developing
a
targeted,
non-viral
delivery
technology
for
gene
therapy,
which
is
designed
to
enable
the
delivery
of
genes
directly
to
the
liver
via
intravenous
injection.
The
Company's
product
offerings
include
REMUNE,
which
is
designed
to
stimulate
an
HIV-infected
individual's
immune
system
to
attack
HIV.
Products
under
development
include
RAVAX,
the
Company's
peptide
vaccine
therapy
being
developed
is
designed
to
stimulate
the
immune
system
of
a
rheumatoid
arthritis
patient;
ZORCELL,
designed
to
stimulate
the
immune
system
of
a
psoriasis
patient
to
regulate
the
disease-causing
T
cells;
and
NeuroVax,
its
proprietary
immune-based
therapy
under
development
for
multiple
sclerosis. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | The
Immune
Response
is
a
biopharmaceutical
company
developing
immune-based
therapies
to
induce
specific
T
cell
response
for
the
treatment
of
HIV,
autoimmune
diseases,
gene
therapy
and
cancer.
For
the
six
months
ended
6/30/01,
revenues
decreased
61%
to
$2.1
million.
Net
loss
applic
to
Com.
before
accounting
change
totalled
$10.5
million,
up
from
$4.1
million.
Results
reflect
decreased
milestone
payment
from
Agouron,
and
decreased
investment
income. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| James Glavin, 65 Chairman | -- | Dennis Carlo, Ph.D., 57 Pres,
CEO, Chief Scientific Officer | $581K | Howard Sampson, 50 CFO,
VP-Fin., Sec., Treasurer | 308K | John Parker, Ph.D. VP
of Regulatory Affairs and Compliance | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|